CRDL · Company research
Cardiol Therapeutics Inc. Class A Common Shares (CRDL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
16records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight | Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight | Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| What Makes Cardiol Therapeutics (TSX:CRDL) A Stock To Watch? - Kalkine Media | What Makes Cardiol Therapeutics (TSX:CRDL) A Stock To Watch? Kalkine Media | View source ↗ | Kalkine Media | Oct 5, 2026 | neutral | 0 | 0.6 |
| Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone - The Globe and Mail | Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone The Globe and Mail | View source ↗ | The Globe and Mail | Sep 24, 2026 | neutral | 0 | 0.6 |
| Fund manager reports 6.4M Cardiol Therapeutics (NASDAQ: CRDL) shares - Stock Titan | Fund manager reports 6.4M Cardiol Therapeutics (NASDAQ: CRDL) shares Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Fewer relapses in heart trial push Cardiol Therapeutics (CRDL) to add patients and delay results - Stock Titan | Fewer relapses in heart trial push Cardiol Therapeutics (CRDL) to add patients and delay results Stock Titan | View source ↗ | Stock Titan | Sep 23, 2026 | neutral | 0 | 0.6 |
| Cash runway into 2028 as Cardiol Therapeutics (CRDL) taps warrants for pivotal heart trial - Stock Titan | Cash runway into 2028 as Cardiol Therapeutics (CRDL) taps warrants for pivotal heart trial Stock Titan | View source ↗ | Stock Titan | Sep 16, 2026 | neutral | 0 | 0.6 |
| Cardiol Therapeutics Stock Falls 3.37%: Is TSX:CRDL Facing Biotech Volatility as Clinical and Funding Risks Persist? - kalkine.ca | Cardiol Therapeutics Stock Falls 3.37%: Is TSX:CRDL Facing Biotech Volatility as Clinical and Funding Risks Persist? kalkine.ca | View source ↗ | kalkine.ca | Aug 28, 2026 | neutral | 0 | 0.6 |
| Cardiol Therapeutics (TSX:CRDL) Rallies 7% as Analyst Upgrades Build on Trial Progress - kalkine.ca | Cardiol Therapeutics (TSX:CRDL) Rallies 7% as Analyst Upgrades Build on Trial Progress kalkine.ca | View source ↗ | kalkine.ca | Aug 26, 2026 | neutral | 0 | 0.6 |
| Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance | Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 25, 2026 | neutral | 0 | 0.6 |
| Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance | Cardiol Therapeutics Inc. (CRDL) is a Great Momentum Stock: Should You Buy? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 24, 2026 | neutral | 0 | 0.6 |
| Cardiol Therapeutics heads to B. Riley summit for July 16 chat - Stock Titan | Cardiol Therapeutics heads to B. Riley summit for July 16 chat Stock Titan | View source ↗ | Stock Titan | Jul 9, 2026 | neutral | 0 | 0.6 |
| CRDL Should I Buy - Intellectia AI | CRDL Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Jun 27, 2026 | neutral | 0 | 0.6 |
| Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long - Yahoo Finance | Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long Yahoo Finance | View source ↗ | Yahoo Finance | Jan 12, 2026 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Mar 9, 2024 | neutral | 0 | 0.6 |
| Cardiol Therapeutics: CRDL Stock Price Quote & News - Robinhood | Cardiol Therapeutics: CRDL Stock Price Quote & News Robinhood | View source ↗ | Robinhood | Jul 22, 2023 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.